InMode Reports Q3 Revenue of $92.5-$93M, Reiterates FY25 Guidance of $365-$375M.

InMode has reiterated its FY25 guidance, expecting Q3 revenue to be between $92.5 million and $93.0 million, and non-GAAP gross margin to be between 77% and 79%. The company also expects full-year 2025 revenue to be between $365 and $375 million, consistent with prior guidance. InMode will release its Q3 financial results on November 5, 2025.

InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, has reiterated its fiscal year 2025 (FY25) guidance. The company expects third quarter (Q3) 2025 revenue to be between $92.5 million and $93.0 million, with a non-GAAP gross margin ranging from 77% to 79%. Additionally, InMode projects full-year 2025 revenue to be between $365 million and $375 million, consistent with its prior guidance InMode to Report Third Quarter 2025 Financial Results and Hold Conference Call on November 5, Expects Q3 Revenue Between $92.5M-$93.0M, Reiterates FY 2025 Guidance Between $365M-$375M^[1].

The company will release its Q3 financial results on November 5, 2025, before the Nasdaq market opens. A conference call to discuss the results is scheduled for the same day at 8:30 a.m. Eastern Time. The conference call will also be webcast live and will be available for replay for 90 days on InMode's investor relations website InMode to Report Third Quarter 2025 Financial Results and Hold Conference Call on November 5, Expects Q3 Revenue Between $92.5M-$93.0M, Reiterates FY 2025 Guidance Between $365M-$375M^[1].

InMode's Q3 revenue projections reflect a continuation of the company's growth trajectory. The expected non-GAAP gross margin indicates strong operational efficiency. The full-year 2025 revenue guidance remains unchanged from the company's prior expectations, demonstrating stability and confidence in its business outlook.

Investors are encouraged to tune in to the conference call and webcast to gain further insights into InMode's financial performance and future prospects. The company's stock has been performing well, closing the last trading session 0.5% higher at $15.23, and has returned 1.1% in the past month Sanuwave Health (SNWV) Surges 9.1%: Is This an Indication of Further Gains?^[2].